The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Inter… (NCT04007055) | Clinical Trial Compass
TerminatedPhase 3
The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
Stopped: Poor recruitment
United States31 participantsStarted 2019-08-09
Plain-language summary
This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.
Who can participate
Age range18 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Peripheral arterial disease
* Planned angioplasty or stenting of superficial femoral artery or popliteal artery.
Exclusion Criteria:
* Patients treated on an emergency basis
* Planned intervention on prior site of open surgical intervention (autogenous or autologous bypass, endarterectomy, or patch angioplasty)
* Planned intervention at site exclusive of superficial femoral artery or popliteal artery
* Planned re-stenting at site of prior stent placement
* Planned re-angioplasty at site of prior angioplasty
* Known inability to tolerate antiplatelet regimen before enrollment
* Patients who plan on receiving follow up care outside the University of Pittsburgh Medical Center
* Current use of prasugrel or ticlopidine
* Current use of oral anticoagulation medication
* Pregnant patients